IDH2 and glioma: Regarding IDH mutation, a strong prognosis-predicting and therapeutic response assessment indicator of gliomas (48), our findings revealed a higher mutation frequency in the low MS4A6A expression group, with exclusive mutant features with PTEN and EGFR alterations, which have been identified as crucial changes in glioma genesis and progression (49, 50).